Latest Conference

The final results of HOPE, a phase 3 open-label extension trial, show high uptake and lower-than-anticipated HIV-1 incidence.

New results indicate that the study met its primary end point for non-inferiority based on the proportion of participants with plasma HIV-1 RNA > 50 copies per mL at week 48.

Glenn Tillotson, PhD, discusses possible avenues for future research on gram-negative skin infections and inappropriate empiric therapy.

With 1329.6 person-years of PrEP use accumulated, early continuation was achieved by 79.8% of participants.

The phase 2a study compares a bivalent combination of Clade C and Mosaic gp140 with a single-valent Clade C gp140.

Providers who received the intervention materials had higher satisfaction and confidence in prescribing chronic opioid therapy than their colleagues who did not.

Matthew Girgis, PharmD, PGY-2, discusses why it's advantageous to decrease patient exposure to vancomycin.

We asked providers in the field why they pursued a career in infectious disease.

Two phase 3 studies presented at IAS 2019 evaluated a switch to B/F/TAF among individuals virologically suppressed on other HIV treatment regimens.

A handful of new studies weighing the risks and benefits of ART regimens containing dolutegravir have triggered new recommendations from the WHO.

The team assessed program engagement, medication refills, and self-reported 3-day adherence over 72 weeks, among the individuals who initiated PrEP.

The difference between NTD prevalence with dolutegravir and non-dolutegravir antiretrovirals from conception was small, but significant at 0.20% difference (95%CI 0.01%, 0.59%).

As little as 10 minutes of ocean swimming can replace the skin microbiome, and bacteria can persist on skin for 24 hours after swimming.

Cases of C auris have been reported in 12 states. Investigators believe they’ve found a new way to attack the fungus using combinations of antifungal and antibacterial medications.

Bacteriophages found in kitchen sponges may hold promise for the treatment of antimicrobial-resistant bacterial infections.

The global emergence of antimicrobial resistance among gram-negative species is a major public health concern.

A symposium at ASM Microbe 2019 considered some specific examples of how bacteriophage shape the microbiome and also zoomed out for a higher-altitude view of the microbiome.

A look at the latest developments in drugs intended to quell gram-positive pathogens, including Clostridioides difficile and non-tuberculosis mycobacterial infections, as presented at ASM Microbe 2019.

Glenn Tillotson, PhD, explains how inappropriate empiric therapy can drive poor outcomes.

Australian investigators conducted an assessment to determine if cannabidiol was effective at killing a range of gram-positive bacteria.

External female catheter could be 1 strategy to reduce the prevalence of CAUTIs.

The research team used single site testing for 1442 (32%) patients with 54 positive (4%) results. Multiple site testing was performed on 3037 (68%) patients and 255 (8%) were positive from at least 1 site tested.

Survey results emphasize the value of educating full-time students with science- and health care-focused majors about vaccines.

De-escalation to monotherapy upon bacteremia resolution did not result in unfavorable outcome differences compared with those who continued combination therapy.

From biosensors to travel screening efforts, here's how DHS is beefing up biodefense.

It's time to use data technology to help tackle epidemics and pandemic preparedness.

Kimberly Claeys, PharmD, discusses the need for more data on rapid diagnostics for gram-negative bloodstream infections.

Develop an exposure plan before a communicable disease event and save yourself time and money.

Research from APIC provides insight into how to strengthen this critical component to patient safety.

Health workers had to act quickly when 30,000 gallons of water spilled into the operating room of a level 1 trauma center in Texas.